 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036. The oncology-focused drug development company has been awarded manufacturing patents in the US and India, while a similar patent has progressed in Australia and is on track to be granted in the coming quarter. 